Central Sleep Apnea in Patients With Coronary Heart Disease Taking P2Y12 Inhibitors.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
received:
24
05
2023
accepted:
13
10
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
5
1
2024
Statut:
epublish
Résumé
Central sleep apnea (CSA) is common in patients with heart failure. Recent studies link ticagrelor use with CSA. We aimed to evaluate CSA prevalence in patients with coronary heart disease (CHD) and whether ticagrelor use is associated with CSA. We reviewed consecutive patients with CHD who underwent a polysomnography (PSG) test over a 5-year period from 3 sleep centers. We sampled patients who were on ticagrelor or clopidogrel during a PSG test at a 1:4 ticagrelor:clopidogrel ratio. Patients with an active opioid prescription during PSG test were excluded. Age, left ventricle (LV) dysfunction, and P2Y12 inhibitor use were included in a multivariate logistic regression. A total of 135 patients were included with 26 on ticagrelor and 109 on clopidogrel (age 64.1 ± 11.4, 32% male). High CSA burden (12%) and strict CSA (4.4%) were more common in patients on ticagrelor than in those on clopidogrel (27% vs. 8.3% and 10.0% vs. 1.8%). Ticagrelor use (vs. clopidogrel) was associated with high CSA burden (OR 3.53, 95% CI 1.04-12.9, P = 0.039) and trended toward significance for strict CSA (OR 6.32, 95% CI 1.03-51.4, P = 0.052) when adjusting for age and LV dysfunction. In an additional analysis also adjusting for history of atrial fibrillation, ticagrelor use and strict CSA became significantly associated (OR 10.0, 95% CI 1.32-117, P = 0.035). CSA was uncommon in patients with CHD undergoing sleep studies. Ticagrelor use (vs. clopidogrel) was associated with high CSA burden and trended toward significance for strict CSA.
Identifiants
pubmed: 38180458
doi: 10.1097/FJC.0000000000001510
pii: 00005344-202401000-00016
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-130Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Eckert DJ, Jordan AS, Merchia P, et al. Central sleep apnea: pathophysiology and treatment. Chest. 2007;131:595–607.
Rowley JA, Badr MS. Central sleep apnea in patients with congestive heart failure. Sleep Med Clin. 2017;12:221–227.
Badr MS, Dingell JD, Javaheri S. Central sleep apnea: a brief review. Curr Pulmonol Rep. 2019;8:14–21.
Hetzenecker A, Buchner S, Greimel T, et al. Cardiac workload in patients with sleep-disordered breathing early after acute myocardial infarction. Chest. 2013;143:1294–1301.
Morbach C, Wagner M, Güntner S, et al. Heart failure in patients with coronary heart disease: prevalence, characteristics and guideline implementation—results from the German EuroAspire IV cohort. BMC Cardiovasc Disord. 2017;17:108.
Revol B, Jullian-Desayes I, Tamisier R, et al. Ticagrelor and central sleep apnea. J Am Coll Cardiol. 2018;71:2378–2379.
Puel V, Théophile H, Godard I, et al. Ticagrelor and central sleep apnoea: impact of withdrawal and reintroduction. Br J Clin Pharmacol. 2019;85:1855–1858.
Paboeuf C, Priou P, Meslier N, et al. Ticagrelor-associated shift from obstructive to central sleep apnea: a case report. J Clin Sleep Med. 2019;15:1179–1182.
Meurin P, Ben Driss A, Defrance C, et al. Central sleep apnea after acute coronary syndrome and association with ticagrelor use. Sleep Med. 2021;80:39–45.
Sabatine MS, Hiatt WR, Goto S, et al. No significant relationship between ticagrelor and sleep apnea in large, randomized, blinded trials. JACC Cardiovasc Interventions. 2020;13:1012–1014.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2009;361:1045–1057.
Wang D, Yee BJ, Grunstein RR, et al. Chronic opioid use and central sleep apnea, where are we now and where to go? A state of the art review. Anesth Analg. 2021;132:1244–1253.
Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the American Academy of sleep medicine. J Clin Sleep Med. 2012;8:597–619.
Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22:667–689.
Strotmann J, Fox H, Bitter T, et al. Predominant obstructive or central sleep apnea in patients with atrial fibrillation: influence of characterizing apneas versus apneas and hypopneas. Sleep Med. 2017;37:66–71.
Harmon EK, Stafford P, Ibrahim S, et al. Atrial fibrillation is associated with central sleep apnea in clinic patients undergoing diagnostic polysomnography. J Arrhythmia. 2020;36:991–996.
Tung P, Levitzky YS, Wang R, et al. Obstructive and central sleep apnea and the risk of incident atrial fibrillation in a community cohort of men and women. J Am Heart Assoc. 2017;6:e004500.
Sjoberg DD, Whiting K, Curry M, et al. Reproducible summary tables with the gtsummary package. R Journey. 2021;13:570–580.
Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686.
Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med. 1999;160:1101–1106.
Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation. 1998;97:2154–2159.
Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63:2503–2509.
Giannoni A, Borrelli C, Gentile F, et al. Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome. Eur Heart J Cardiovasc Pharmacother. 2021;7:180–188.
Giannoni A, Emdin M, Passino C. Cheyne-Stokes respiration, chemoreflex, and ticagrelor-related dyspnea. N Engl J Med. 2016;375:1004–1006.
Iber C. Are we ready to define central hypopneas? Sleep. 2013;36:305–306.
Linz D, Hendriks J. Central sleep apnea in atrial fibrillation: risk factor or marker of untreated underlying disease?. Int J Cardiol Heart Vasc. 2020;30:100650.
Sanchez AM, Germany R, Lozier MR, et al. Central sleep apnea and atrial fibrillation: a review on pathophysiological mechanisms and therapeutic implications. Int J Cardiol Heart Vasc. 2020;30:100527.
He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996–1002.
Drager LF, McEvoy RD, Barbe F, et al. Sleep apnea and cardiovascular disease: lessons from recent trials and need for team science. Circulation. 2017;136:1840–1850.
Javaheri S, Shukla R, Zeigler H, et al. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol. 2007;49:2028–2034.